Johnson & Johnson Raises 2026 Guidance Despite Sharp Q1 Profit Decline

Johnson & Johnson reported a mixed first quarter, characterized by strong top-line growth and a raised annual outlook, offset by a steep decline in net profit. The company is pivoting toward accelerated growth in its core segments, leveraging its Innovative Medicine and MedTech portfolios to drive revenue, even as bottom-line figures faced pressure this quarter. Financial results for the period showed sales rising 9.9% to $24.06 billion, up from $21.89 billion a year ago. Growth was broad-based, with U.S. sales increasing 8.3% to $13.33 billion and international sales climbing 12% to $10.73 billion. Segment performance was led by Innovative Medicine, which saw sales grow 11.2% to $15.43 billion, and MedTech, which grew 7.7% to $8.64 billion. However, the bottom line saw a significant contraction. Net earnings plummeted 52.4% to $5.24 billion, and earnings per share (EPS) fell to $2.14 from $4.54 in the prior year. Adjusted net earnings were slightly lower at $6.61 billion, or $2.70 per share, compared to $6.71 billion a year ago. Looking forward, the company has upgraded its fiscal 2026 projections. JNJ now expects adjusted earnings in a range of $11.45 to $11.65 per share, with a midpoint of $11.55. Annual sales forecasts have also been lifted to a range between $100.3 billion and $101.3 billion, representing a midpoint growth of 7% year-over-year. In a move to reward shareholders, the Board of Directors declared a 3.1% increase in the quarterly dividend, raising it to $1.34 per share. Despite the raised guidance and dividend hike, shares traded lower by approximately 1.6% at $234.00 in pre-market activity following the announcement.